TY - JOUR
T1 - Potential effects of curcumin in the treatment of COVID-19 infection
AU - Zahedipour, Fatemeh
AU - Hosseini, Seyede Atefe
AU - Sathyapalan, Thozhukat
AU - Majeed, Muhammed
AU - Jamialahmadi, Tannaz
AU - Al-Rasadi, Khalid
AU - Banach, Maciej
AU - Sahebkar, Amirhossein
N1 - Funding Information:
MB has served on the speaker's bureau and as an advisory board member for Amgen, Sanofi, Aventis and Lilly. NK has given talks, attended conferences and participated in trials sponsored by Amgen, Angelini, Astra Zeneca, Boehringer Ingelheim, Galenica, MSD, Novartis, Novo Nordisk, Sanofi, and WinMedica. KR received a research grant from Sanofi, and served on the speaker's bureau and as an advisory board member for Sanofi, Astra Zeneca and Pfizer. Muhammed Majeed is the founder of Sabinsa Corporation and Sami Labs Ltd.
Funding Information:
MB has served on the speaker's bureau and as an advisory board member for Amgen, Sanofi, Aventis and Lilly. NK has given talks, attended conferences and participated in trials sponsored by Amgen, Angelini, Astra Zeneca, Boehringer Ingelheim, Galenica, MSD, Novartis, Novo Nordisk, Sanofi, and WinMedica. KR received a research grant from Sanofi, and served on the speaker's bureau and as an advisory board member for Sanofi, Astra Zeneca and Pfizer. Muhammed Majeed is the founder of Sabinsa Corporation and Sami Labs Ltd.
Publisher Copyright:
© 2020 John Wiley & Sons, Ltd.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Coronavirus disease 2019 (COVID-19) outbreak is an ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with considerable mortality worldwide. The main clinical manifestation of COVID-19 is the presence of respiratory symptoms, but some patients develop severe cardiovascular and renal complications. There is an urgency to understand the mechanism by which this virus causes complications so as to develop treatment options. Curcumin, a natural polyphenolic compound, could be a potential treatment option for patients with coronavirus disease. In this study, we review some of the potential effects of curcumin such as inhibiting the entry of virus to the cell, inhibiting encapsulation of the virus and viral protease, as well as modulating various cellular signaling pathways. This review provides a basis for further research and development of clinical applications of curcumin for the treatment of newly emerged SARS-CoV-2.
AB - Coronavirus disease 2019 (COVID-19) outbreak is an ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with considerable mortality worldwide. The main clinical manifestation of COVID-19 is the presence of respiratory symptoms, but some patients develop severe cardiovascular and renal complications. There is an urgency to understand the mechanism by which this virus causes complications so as to develop treatment options. Curcumin, a natural polyphenolic compound, could be a potential treatment option for patients with coronavirus disease. In this study, we review some of the potential effects of curcumin such as inhibiting the entry of virus to the cell, inhibiting encapsulation of the virus and viral protease, as well as modulating various cellular signaling pathways. This review provides a basis for further research and development of clinical applications of curcumin for the treatment of newly emerged SARS-CoV-2.
KW - acute respiratory distress syndrome
KW - curcuminoids
KW - pulmonary fibrosis
KW - viral infection
UR - http://www.scopus.com/inward/record.url?scp=85087181943&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087181943&partnerID=8YFLogxK
U2 - 10.1002/ptr.6738
DO - 10.1002/ptr.6738
M3 - Review article
C2 - 32430996
AN - SCOPUS:85087181943
SN - 0951-418X
VL - 34
SP - 2911
EP - 2920
JO - Phytotherapy Research
JF - Phytotherapy Research
IS - 11
ER -